Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Deloitte
Teva
Daiichi Sankyo
Argus Health
Novartis
Harvard Business School
Cerilliant
Federal Trade Commission
Dow

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,723,361

« Back to Dashboard

Summary for Patent: 7,723,361
Title:Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:11/096,155
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,723,361

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,723,361

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 218865 ➤ Sign Up
Austria 304356 ➤ Sign Up
Australia 676722 ➤ Sign Up
Australia 6248694 ➤ Sign Up
Brazil 9400764 ➤ Sign Up
Canada 2157288 ➤ Sign Up
Canada 2342974 ➤ Sign Up
Canada 2512926 ➤ Sign Up
Colombia 4230017 ➤ Sign Up
Germany 69430796 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
McKinsey
US Army
Cantor Fitzgerald
Accenture
Merck
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot